Hepatocellular Cancer (HCC) is the most common primary liver cancer and a major cause of cancer-related deaths worldwide. Traditionally, outcomes have been poor, but much success has been seen recently with immunotherapy for advanced HCC. For early disease, liver transplant can treat the cancer as well as the underlying liver disease (cirrhosis). At the University of Cincinnati Cancer Center, we are trying to combine the two approaches to achieve even greater treatment success – immunotherapy and transplant. It is important to note that immunotherapy is a relatively new area of research, and more information is needed to fully determine its safety and effectiveness.

UCCC-GI-21-01 Immunotherapy Prior to Liver Transplant for Hepatocellular Cancer (HCC) is designed to assess the safety and effectiveness of immunotherapy and identify factors that may predict treatment response. Due to factors including blood type, the severity of the condition, and the availability of donor livers in the region, patients often wait up to 6 months for transplants. Patients in this study will receive immunotherapy for 4 months during this waiting period.

There is currently no established standard of care for systemic treatment for patients with HCC who are awaiting a liver transplant. Due to this, the UCCC-GI-21-01 clinical trial could greatly impact the community, both in terms of improving treatment options and advancing our understanding of the disease. The UC Health liver transplant program is highly regarded and provides expert care for patients with liver disease, including those with HCC who may be candidates for liver transplants. The Ohio Cancer Incidence Surveillance System (OCISS) shows liver cancer incidence rates in the Cincinnati area have been increasing over the past several decades.

All patients with HCC who are eligible for liver transplant listing may qualify for the UCCC-GI-21-01 trial. Referrals are welcome!

To learn more about this clinical trial, contact UCCC Clinical Trials Office at 513-584-7698 or email team3giandgu@ucmail.uc.edu to reach our clinical research staff. You can also find the trial on the High Enroll app.